Disc Medicine Operating Income Over Time
| IRON Stock | 56.18 1.68 3.08% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Disc Medicine Performance and Disc Medicine Correlation. Disc |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Disc Medicine. If investors know Disc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Disc Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Disc Medicine is measured differently than its book value, which is the value of Disc that is recorded on the company's balance sheet. Investors also form their own opinion of Disc Medicine's value that differs from its market value or its book value, called intrinsic value, which is Disc Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Disc Medicine's market value can be influenced by many factors that don't directly affect Disc Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Disc Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Disc Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Disc Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Operating Income Analysis
Compare Disc Medicine and related stocks such as Anebulo Pharmaceuticals, Adagene, and Acrivon Therapeutics, Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANEB | (173.3 K) | (173.3 K) | (173.3 K) | (173.3 K) | (173.3 K) | (173.3 K) | (173.3 K) | (173.3 K) | (173.3 K) | (173.3 K) | (3.6 M) | (6.8 M) | (11.8 M) | (8.3 M) | (7.5 M) | (7.9 M) |
| ADAG | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (19.2 M) | (19.2 M) | (72.4 M) | (83.9 M) | (23.7 M) | (21.3 M) | (22.4 M) |
| ACRV | (3.2 M) | (3.2 M) | (3.2 M) | (3.2 M) | (3.2 M) | (3.2 M) | (3.2 M) | (3.2 M) | (3.2 M) | (3.2 M) | (3.2 M) | (16.2 M) | (32.7 M) | (67.2 M) | (60.5 M) | (57.5 M) |
| ANAB | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | 4.9 M | (3.3 M) | (3 M) | (28.8 M) | (66.7 M) | (107.4 M) | (23.9 M) | (56.8 M) | (115.2 M) | (164.4 M) | (148 M) | (140.6 M) |
| MLYS | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (18.7 M) | (31.5 M) | (84.7 M) | (192.4 M) | (182.8 M) |
| OLMA | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (4.3 M) | (21.5 M) | (71.5 M) | (107 M) | (105 M) | (94.5 M) | (89.7 M) |
| LRMR | (35.5 M) | (35.5 M) | (35.5 M) | (35.5 M) | (35.5 M) | (73.8 M) | (57.1 M) | (53.9 M) | (62.7 M) | (23.2 M) | (42.8 M) | (50.5 M) | (36.5 M) | (41.8 M) | (48 M) | (50.4 M) |
| FENC | (1.6 M) | (3.4 M) | (3.6 M) | (1.9 M) | (2.9 M) | (1.9 M) | (2.9 M) | (7 M) | (10.4 M) | (13 M) | (17.9 M) | (17.2 M) | (22.6 M) | (12.8 M) | (11.5 M) | (12.1 M) |
| OBIO | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (21.8 M) | (32.7 M) | (51.5 M) | (46.4 M) | (48.7 M) |
| BMEA | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (5.3 M) | (41.7 M) | (83.6 M) | (126.1 M) | (113.5 M) | (107.8 M) |
| GPCR | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (15.9 K) | (37.7 K) | (52.6 M) | (102.8 M) | (92.5 M) | (87.9 M) |
| TERN | (18.5 M) | (18.5 M) | (18.5 M) | (18.5 M) | (18.5 M) | (18.5 M) | (18.5 M) | (18.5 M) | (18.5 M) | (70.2 M) | (37 M) | (49.9 M) | (62 M) | (102.6 M) | (92.3 M) | (87.7 M) |
| DAWN | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (13.8 M) | (72.7 M) | (146.9 M) | (206.1 M) | (217.3 M) | (206.4 M) |
| ABOS | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.9 M) | 61.6 M | (45.2 M) | (61.1 M) | (55 M) | (52.3 M) |
| MLTX | (105.8 K) | (105.8 K) | (105.8 K) | (105.8 K) | (105.8 K) | (105.8 K) | (105.8 K) | (105.8 K) | (105.8 K) | (105.8 K) | (105.8 K) | (4.6 M) | (65.1 M) | (54.1 M) | (143.1 M) | (135.9 M) |
| CRNX | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (9.1 M) | (28.7 M) | (53.8 M) | (75 M) | (107.7 M) | (167.9 M) | (222.6 M) | (338.9 M) | (321.9 M) |
| CNTA | (5.1 M) | (5.1 M) | (5.1 M) | (5.1 M) | (5.1 M) | (5.1 M) | (5.1 M) | (5.1 M) | (5.1 M) | (5.1 M) | (10.4 M) | (139.3 M) | (212.3 M) | (171.3 M) | (154.2 M) | (161.9 M) |
| TRDA | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (11.8 M) | (26.7 M) | (51.1 M) | (97.2 M) | (3.2 M) | 47 M | 49.4 M |
Disc Medicine and related stocks such as Anebulo Pharmaceuticals, Adagene, and Acrivon Therapeutics, Operating Income description
Operating Income is the amount of profit realized from Disc Medicine operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Disc Medicine is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Disc Medicine | IRON |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
null 56.18
Check out Disc Medicine Performance and Disc Medicine Correlation. To learn how to invest in Disc Stock, please use our How to Invest in Disc Medicine guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Disc Medicine technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.